Pinnacle Medicines, a biotechnology company focused on oral peptide therapeutics, announced it has closed an oversubscribed $89 million Series B financing round to advance its pipeline into clinical trials. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed.
With this latest financing, the company has raised a total of $134 million to date following its incubation by OrbiMed and other healthcare-focused investors. The proceeds will be used to advance Pinnacle’s lead programs through clinical proof of concept, with an initial focus on immunology and cardiometabolic diseases, while also expanding its proprietary peptide discovery platform and research and development capabilities.
Pinnacle Medicines is developing a new generation of oral peptide drugs designed to deliver biologic-level safety and efficacy with the convenience of oral dosing. Its platform integrates artificial intelligence with physics-based simulations and advanced peptide chemistry to design and optimize therapeutic candidates. The company aims to unlock the broader potential of peptides across chronic disease areas by overcoming traditional delivery challenges associated with injectable biologics.
Investors highlighted the company’s rapid progress in building both its discovery platform and pipeline, positioning it as an emerging leader in oral peptide therapeutics as it moves toward clinical-stage development.
KEY QUOTES:
“This financing marks an important milestone for Pinnacle Medicines and reflects strong conviction in the transformative potential of oral peptide therapeutics. At Pinnacle, we are building a platform designed to unlock the full therapeutic potential of peptides through oral delivery. With this strong group of investors, we are now focused on translating that vision into clinical proof of concept and delivering transformative medicines for patients.”
Jonathan Wang, Chief Executive Officer of Pinnacle Medicines
“We have assembled an experienced peptide drug discovery and development team spanning all key disciplines and built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. The rapid progression of our pipeline reflects the strength of this approach and positions us to advance a new generation of oral peptide medicines for chronic diseases.”
Chengzao Sun, Ph.D., Chief Scientific Officer and Co-Founder of Pinnacle Medicines
“We are very excited about the future of oral peptide therapeutics, and Pinnacle Medicines is emerging as a leader in this field. The team brings deep experience in peptide drug development and has demonstrated a remarkable ability to rapidly build both a differentiated discovery platform and a promising first-in-class pipeline. We look forward to supporting the company as it accelerates these programs toward clinical development.”
Cindy Xiong, Partner at Foresite Capital
“We have supported Pinnacle Medicines since inception and have been impressed by the team’s scientific vision and execution. Oral peptide therapeutics have the potential to reshape treatment paradigms across multiple disease areas, and we are excited to continue supporting the company as it advances its pipeline toward clinical proof of concept.”
David Wang, M.D., Ph.D., Partner and Senior Managing Director at OrbiMed
